‘Mustafa(Pbuh) Prize commended Ugur Sahin’s achievements prior to any other scientific institution’
DW published a report on the 2019 Mustafa(Pbuh) Prize laureate’s success in developing COVID-19 vaccine with 90% efficacy.
MSTF Media reports:
Last November, during the 3rd round of the Mustafa Prize Award Ceremony, Ugur Sahin was awarded the 2019 Mustafa Prize in Life and Medical Science and Technology for his achievements in “Development and Clinical Testing of mRNA-based Cancer Vaccines that are Tailored to the Mutation Profile of a Cancer Patient.”
Born in Turkey, Sahin is now a professor of oncology and immunology at the University of Mainz in Germany, and is the chief executive and co-founder of BioNTech company.
As the world is struggling with COVID-19 pandemic, the 2019 Mustafa Prize laureate, Ugur Sahin, has come to commendable achievements.
In this regard, the German Deutsche Welle (DW) has broadcast a report on Ugur Sahin’s life and his achievements in developing COVID-19 vaccine, highlighting that the vaccine developed by him has the strongest possibility for defeating Coronavirus.
This report throws light on the fruits of the demanding research to which the whole world looked forward, and further refers to the vaccine that will massacre the Coronavirus which has upended the world.
Sahin, 55, is a Turkish physician born in Iskenderun. The family moved to Cologne, Germany, when he was a four-year-old child. He earned his PhD (Hons.) in 1992, completing a thesis on immunotherapy treatment for cancer cells.
DW’s report also comments on Ugur Sahin’s being selected as a 2019 Mustafa Prize laureate, stating: “This Prize [Mustafa Prize] is the top scientific award in the Islamic world, which is worth 500,000 USD. It is safe to say that the Mustafa Prize appreciated Dr. Ugur Sahin prior to any other persuasive-scientific institution and lavished praise on him.”
BioNTech and its U.S. partner, Pfizer, are developing an effective COVID-19 vaccine, which has garnered worldwide attention. It is expected that 100 million doses of the vaccine be produced and made available to people by the end of 2020.
DW’s report further notes that the U.S. government has agreed to pay Pfizer and BioNTech nearly $2 billion for their potential Coronavirus vaccine. Due to these developments, the value of BioNTech shares soared to more than €20 billion, making Ugur Sahin a billionaire in Germany.
It is worth mentioning that Rassoul Dinarvand, head of the ‘Life and Medical Science and Technology’ category of the Mustafa Prize, attending an Iranian national TV program, touched upon the mRNA-based vaccine developed by Ugur Sahin, the 2019 Mustafa Prize laureate, saying: “At least 100 million doses of BioNTech vaccine have been produced and are on the brink of getting final approval. In fact, these companies have accepted the investment risk in regard to the global Coronavirus issue. However, the European Union, the United States, and some other countries have already provided some support so that the vaccine be released sooner.”
